Park National Corp OH Sells 20,162 Shares of Astrazeneca Plc $AZN

Park National Corp OH trimmed its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 12.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 139,437 shares of the company’s stock after selling 20,162 shares during the period. Park National Corp OH’s holdings in Astrazeneca were worth $12,818,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Binnacle Investments Inc raised its holdings in Astrazeneca by 21.8% during the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after acquiring an additional 118 shares in the last quarter. Chapin Davis Inc. boosted its position in Astrazeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after purchasing an additional 120 shares during the last quarter. 44 Wealth Management LLC grew its stake in Astrazeneca by 0.7% in the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after purchasing an additional 124 shares in the last quarter. CoreCap Advisors LLC increased its position in shares of Astrazeneca by 30.6% during the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after purchasing an additional 125 shares during the last quarter. Finally, Highline Wealth Partners LLC increased its position in shares of Astrazeneca by 32.0% during the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after purchasing an additional 129 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Citigroup initiated coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They set a “buy” rating on the stock. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Guggenheim reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, HSBC reissued a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a research report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Stock Up 0.2%

Shares of AZN stock opened at $188.76 on Friday. Astrazeneca Plc has a 52 week low of $122.48 and a 52 week high of $212.71. The stock has a market cap of $292.75 billion, a P/E ratio of 28.82, a P/E/G ratio of 1.42 and a beta of 0.32. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date is Friday, February 20th. Astrazeneca’s payout ratio is currently 66.26%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.